Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $13 | $4 | $9 | $33 |
| % Growth | 201.7% | -55.2% | -71.2% | – |
| Cost of Goods Sold | $8 | $5 | $2 | $1 |
| Gross Profit | $5 | -$1 | $8 | $32 |
| % Margin | 35.5% | -24.4% | 81.7% | 96.9% |
| R&D Expenses | $48 | $37 | $28 | $36 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $80 | $68 | $56 | $27 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $128 | $105 | $84 | $63 |
| Operating Income | -$123 | -$106 | -$77 | -$32 |
| % Margin | -971.7% | -2,511.5% | -816.8% | -97.1% |
| Other Income/Exp. Net | $48 | $41 | -$18 | $22 |
| Pre-Tax Income | -$75 | -$65 | -$97 | -$9 |
| Tax Expense | -$52 | -$45 | $4 | -$22 |
| Net Income | -$24 | -$20 | -$101 | $12 |
| % Margin | -187% | -482.3% | -1,071.9% | 38.1% |
| EPS | -0.17 | -0.18 | -0.73 | 0.09 |
| % Growth | 5.6% | 75.3% | -912% | – |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| Weighted Avg Shares Out | 139 | 113 | 138 | 138 |
| Weighted Avg Shares Out Dil | 139 | 113 | 138 | 138 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $4 | $0 | $3 | $0 |
| Depreciation & Amortization | -$46 | -$47 | $1 | -$20 |
| EBITDA | -$169 | -$152 | -$75 | -$52 |
| % Margin | -1,334.5% | -3,622.3% | -801.5% | -158.8% |